Cargando…

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resulting in partial restoration of immune function. The incidence of and risk factors for SPM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688551/ https://www.ncbi.nlm.nih.gov/pubmed/32704159 http://dx.doi.org/10.1038/s41375-020-0987-6

Ejemplares similares

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
por: Quartermaine, Cooper, et al.
Publicado: (2023)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
por: Guinn, Daphne, et al.
Publicado: (2017)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
por: Sampietro, Marta, et al.
Publicado: (2023)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib
por: Jackson, Ross A., et al.
Publicado: (2023)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
por: Chen, Sunnia T., et al.
Publicado: (2022)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
por: Shorer Arbel, Yamit, et al.
Publicado: (2021)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
por: Blum, Kristie A., et al.
Publicado: (2011)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition
por: Pepper, C, et al.
Publicado: (2015)

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma
por: Zent, Clive S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbrjnbkahigndp398mjr221bu0